Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2016 May 30;18(Suppl 3):iii104. doi: 10.1093/neuonc/now076.30

MB-32: MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Timothy Phoenix 1, Deanna Patmore 2, Scott Boop 1, Nidal Boulos 1, Megan Jacus 1, Yogesh Patel 1, Martine Roussel 1, David Finkelstein 1, Liliana Goumnerova 3, Sebastien Perreault 4, Elizabeth Wadhwa 4, Yoon-Jae Cho 4, Clinton Stewart 1, Richard Gilbertson 2
PMCID: PMC4903589

The childhood brain tumor medulloblastoma includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant Beta-Catenin in WNT-medulloblastoma – an essentially curable form of the disease – induce an aberrant fenestrated vasculature that permits the accumulation of high levels of intra-tumoral chemotherapy and a robust therapeutic response. In contrast, SHH-medulloblastoma – a less curable disease subtype – contains an intact blood brain barrier, rendering this tumor impermeable and resistant to chemotherapy. Remarkably, the medulloblastoma-endothelial cell paracrine axis can be manipulated in vivo, altering chemotherapy permeability and clinical response. Thus, medulloblastoma genotype dictates tumor microenvironment and subsequent vessel phenotype, explaining in part the disparate prognoses among medulloblastoma subtypes and suggesting an approach to enhance the chemoresponsiveness of other brain tumors.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES